scholarly journals Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

2022 ◽  
Vol Volume 15 ◽  
pp. 155-163
Author(s):  
Yu Zhou ◽  
Mingyu Chen ◽  
Libin Liu ◽  
Zhou Chen
Keyword(s):  
Real World ◽  
Receptor Agonists ◽  
Gastrointestinal Risk

Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1291-P
Author(s):  
CRAIG I. COLEMAN ◽  
WILLIAM H. HERMAN ◽  
SHIVANI PANDYA ◽  
LI WANG ◽  
ONUR BASER ◽  
...  
Keyword(s):  
Body Weight ◽  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 247-OR ◽  
Author(s):  
ELISABETTA PATORNO ◽  
AJINKYA PAWAR ◽  
SEBASTIAN SCHNEEWEISS ◽  
ROBERT J. GLYNN ◽  
DAE H. KIM ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Real World ◽  
Sglt2 Inhibitors ◽  
Receptor Agonists

Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations

Blood Reviews ◽  
2020 ◽  
Vol 41 ◽  
pp. 100647 ◽  
Author(s):  
F. Zaja ◽  
M. Carpenedo ◽  
C. Baratè ◽  
A. Borchiellini ◽  
F. Chiurazzi ◽  
...  
Keyword(s):  
Real World ◽  
Immune Thrombocytopenia ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor
Sign in / Sign up

Export Citation Format

Share Document